# Implementation of Biomarkers 2027

**Funder:** KWF
**Budget:** €1M–€4M
**Deadline:** 20 October 2026 (Pre-proposal deadline: 20 October 2026 at 12:00 noon. Full proposal deadline: 23 February 2027 at 12:00 noon.)
**Duration:** 3-5 years
**Consortium:** Required — minimum 4 participating parties (may include private partners)
**Application:** 2-stage: pre-proposal (opens 25 Aug 2026, closes 20 Oct 2026) → full proposal (opens 15 Dec 2026, closes 23 Feb 2027) → interviews (May 2027) → funding decision (June 2027)
**TRL:** 7-9
**Frequency:** Annual
**Eligible countries:** NL
**Official call:** https://www.kwf.nl/en/forresearchers/funding/implementation-of-biomarkers-2027
**Last verified:** 24 June 2026

## Eligibility & scope

Open to multidisciplinary consortia (min. 4 parties) at Dutch institutions aiming to implement a clinically validated oncology biomarker at national scale (TRL 7–9). Mandatory components include an HTA specialist in the team, a KWF-approved steering committee, and a patient perspective embedded throughout. Public-private collaborations encouraged; PhD candidates strongly discouraged. Proposals must be submitted via KWF GMS.

## Summary

The KWF Implementation of Biomarkers 2027 call funds multidisciplinary consortia to roll out clinically validated oncology biomarkers (technology readiness level 7-9) across the Netherlands, with budgets of €1-4 million over 3-5 years. The call is open to groups of at least four parties, including academic, clinical, and private partners, and requires health technology assessment expertise, a project manager, and patient involvement in the steering committee. This is a two-stage, consortium-driven implementation pathway for near-market biomarker technologies seeking nationwide adoption and co-funding support.

## Who should apply

- Consortium lead with capacity to coordinate minimum four participating organisations across academia, clinical practice, and industry
- Teams with integrated health technology assessment (HTA) expertise and a dedicated project manager
- Biomarker developers and diagnostic partners ready for nationwide rollout (TRL 7-9 technologies)
- Consortia including patient representatives in governance and co-funding commitments from private or healthcare sector partners

## Key dates

- Pre-proposal deadline: 20 October 2026 at 12:00 noon UTC; full proposal deadline 23 February 2027 at 12:00 noon UTC
- Two-stage process: pre-proposal evaluation, shortlist progresses to full proposal, interviews May 2027, funding decision June 2027
- Project duration 3-5 years

## Tips for applicants

- Consortium size matters: assemble four parties early and assign a strong project manager; KWF penalises loose or under-resourced management structures.
- HTA is mandatory: include a named health economist or HTA specialist and evidence of reimbursement pathway analysis; implementation without health-economic modelling will stall at pre-proposal review.
- Patient and stakeholder integration is not optional: detail patient co-design in governance, steering-committee roles, and dissemination; KWF panels check for meaningful involvement, not tokenism.

## Frequently asked questions

### What is the budget range for the KWF Implementation of Biomarkers 2027 call?

Budgets range from €1 million to €4 million per project. Co-funding from consortium partners is encouraged and strengthens proposals.

### Who is eligible to apply for the Implementation of Biomarkers 2027 call?

Multidisciplinary consortia of at least four parties (academic, clinical, and private entities) based in the Netherlands. PhD candidates are strongly discouraged as lead applicants.

### Is the Implementation of Biomarkers 2027 call a one-stage or two-stage process?

It is two-stage: pre-proposal (by 20 October 2026), followed by full proposal (by 23 February 2027) for shortlisted groups. Shortlisted groups are interviewed in May 2027.

### What technology readiness level (TRL) is required for biomarkers in this call?

Biomarkers must be at TRL 7-9, meaning clinically validated and ready for implementation or scaling in routine clinical practice.

### Can private companies partner in the Implementation of Biomarkers 2027 consortium?

Yes, public, private collaborations are encouraged and co-funding from industry or healthcare partners is welcome and strengthens the proposal.

---

Source: [The Great Grantsby](https://grantsby.eu/grants/kwf-implementation-of-biomarkers-2027-2026-10) — EU grant monitoring for academic researchers. Always verify details on the funder's website before applying.